TITLE

Long-Term Efficacy and Safety of Linagliptinin Patients With Type 2 Diabetes and Severe Renal Impairment

AUTHOR(S)
MCGILL, JANET B.; SLOAN, LANCE; NEWMAN, JENNIFER; PATEL, SANJAY; SAUCE, CHRISTOPHE; VON EYNATTEN, MAXIMILIAN; WOERLE, HANS-JUERGEN
PUB. DATE
February 2013
SOURCE
Diabetes Care;Feb2013, Vol. 36 Issue 2, p237
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI). RESEARCH DESIGN AND METHODS--In this 1-year, double-blind study, 133 patients with type 2 diabetes (HbA1c 7.0-10.0%) and severe RI (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²) at screening were randomized to linagliptin 5 mg (n = 68) or placebo (n = 65) once daily, added to existing background therapy. The primary efficacy end point was HbA1c change from baseline to week 12. Efficacy and safety end points were assessed after 1 year. RESULTS--At week 12, adjusted mean HbA1c decreased by -0.76% with linagliptin and 20.15% with placebo (treatment difference, -0.60%; 95% CI -0.89 to -0.31; P < 0.0001). HbA1c improvements were sustained with linagliptin (-0.71%) over placebo (0.01%) at 1 year (treatment difference -0.72%, -1.03 to -0.41; P < 0.0001). Mean insulin doses decreased by -6.2 units with linagliptin and -0.3 units with placebo. Overall adverse event incidence was similar over 1 year (94.1 vs. 92.3%). Incidence of severe hypoglycemia with linagliptin and placebo was comparably low (three patients per group). Linagliptin and placebo had little effect on renal function (median change in eGFR, -0.8 vs. -2.2 mL/min/1.73 m²), and no drug- related renal failure occurred. CONCLUSIONS--In patients with type 2 diabetes and severe RI, linagliptin provided clinically meaningful improvements in glycemic control with very low risk of severe hypoglycemia, stable body weight, and no cases of drug-related renal failure. The potential for linagliptin to spare insulin and provide long-term renal safety warrants further investigations.
ACCESSION #
85125679

 

Related Articles

  • Renal/Hormonal Mechanisms in the Pathogenesis of Edema with Thiazolidinediones. Mudaliar, Sunder; Chao, Edward; Aroda, Vanita; Chang, Anna; Burke, Paivi; O'connot, Daniel T.; Henry, Robert R. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA86 

    The article discusses the results of a clinical study examining the renal/hormonal mechanisms causing edema with thiazolidinedione in patients with type 2 diabetes mellitus (DM2). The study involved 25 obese DM2 patients who were randomized to receive pioglitazone (PIO) with insulin (INS) and...

  • Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes. Gadsby, Roger // Clinical Medicine: Therapeutics;2009, Issue 1, p53 

    Background: Sitagliptin was launched into the UK Market in 2007, as the fi rst member of a new class of oral glucose lowering medications, the Dipetidyl Peptidase 4 inhibitors. Aim: To review the effi cacy and safety of sitagliptin and discuss its place in therapy. Method: Expert review using...

  • Insulin Myths and Facts.  // Clinical Diabetes;Winter2007, Vol. 25 Issue 1, p39 

    The article presents information on several myths and facts about insulin. The indication of using insulin as a failure of diabetes management is a myth. Diabetes is considered as an insulin problem not as many people think that it is a sugar problem. Weight gain could be experience by patients...

  • Ramadan fast and control of diabetes. Chandalia, Hemraj B. // International Journal of Diabetes in Developing Countries;Apr-Jun2006, Vol. 26 Issue 2, p49 

    The author reflects on the results of a study on the effect of pioglitazone on fasting Muslim subjects during Ramadan. He says that fructosamine was appropriately utilized as a parameter to evaluate metabolic control. Standardization is needed in a test using fructosamine. The Indian...

  • Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients. Kakizaki, Satoru; Takizawa, Daichi; Yamazaki, Yuichi; Nakajima, Yuka; Ichikawa, Takeshi; Sato, Ken; Takagi, Hitoshi; Mori, Masatomo; Kasama, Kazunori // Journal of Gastroenterology;2008, Vol. 43 Issue 1, p86 

    Background. The number of patients with morbid obesity is increasing worldwide. However, the prevalence of morbid obesity is still low in Japan, and therefore few systematic investigations of liver dysfunction in this population have so far been carried out. This study aimed to investigate the...

  • The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype mice. Paglialunga, Sabina; Fisette, Alexandre; Munkonda, Mercedes; Ying Gao; Richard, Denis; Cianflone, Katherine // BMC Physiology;2010, Vol. 10, p4 

    Background: Acylation stimulating protein (ASP) is an adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes. Previous studies have shown that ASP-deficient C3 knockout mice are hyperphagic yet lean, as they display increased oxygen consumption and...

  • Where do conventional OADs stand. Sahay, Rakesh Kumar; Nagesh, V. Sri // Indian Journal of Endocrinology & Metabolism;Dec2012 Supplement, Vol. 16, pS252 

    The last two decades have witnessed unprecedented activity in the field of OADs with many new drugs becoming available. Concerns with OAD include cardiovascular safety, fear about hypoglycemia, weight gain etc. In this article we attempt to review OADs, sulfonylureas in particular, in the light...

  • Rosiglitazone Reduced the Incidence of Diabetes in Patients With Impaired Glucose Tolerance. Pignone, Michael // Clinical Diabetes;Winter2007, Vol. 25 Issue 1, p23 

    The article focuses on the results of a study on the reduction of the incidence of diabetes in patients with impaired glucose tolerance by rosiglitazone. The reduction is associated with a small excess risk of heart failure and weight gain. These findings add to existing evidence suggesting that...

  • Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Miyako Kishimoto // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;2013, Vol. 6, p187 

    Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics